Literature DB >> 7123514

Dosage frequency for suppression of platelet function by low dose aspirin therapy.

B A Bradlow, N Chetty.   

Abstract

A study of platelet aggregation and MDA production after an oral dose of 300 mg aspirin indicated that partial recovery of platelet function occurred when approximately one third of the circulating platelets had been replaced by new (uninhibited) platelets. In vitro studies on mixtures of normal and aspirin inhibited platelets indicated partial restoration of platelet aggregation and thromboxane B2 production with as little as 10% of normal platelets in some subjects. Restoration of full function required a higher proportion of normal platelets. There was considerable variation between subjects. These data suggest that complete suppression of platelet functions in all normal subjects requires daily administration of the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7123514     DOI: 10.1016/0049-3848(82)90283-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Obesity and Altered Aspirin Pharmacology.

Authors:  Nicholas B Norgard
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 2.  Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.

Authors:  Joonseok Kim; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

3.  Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2).

Authors:  B M Biccard; A Sigamani; M T V Chan; D I Sessler; A Kurz; J G Tittley; T Rapanos; J Harlock; D Szalay; M E Tiboni; E Popova; S M Vásquez; B Kabon; M Amir; M Mrkobrada; B R Mehra; H El Beheiry; E Mata; B Tena; S Sabaté; M K Zainal Abidin; V R Shah; K Balasubramanian; P J Devereaux
Journal:  Br J Surg       Date:  2018-07-18       Impact factor: 6.939

4.  Elective percutaneous liver biopsy and use of aspirin.

Authors:  Maxence Emmanuel Reynard; Jean-François Dufour
Journal:  United European Gastroenterol J       Date:  2022-06-02       Impact factor: 6.866

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.